Stockscreener 앱 받기
65.55
2.25%
-1.51
시간 외 거래:
65.55
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics chief medical officer sells $462k in ORKA stock - Investing.com Canada
Up nearly 840% in a year, does this 'strong buy' stock have more room to run? - MSN
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Oruka Therapeutics stock hits 52-week high at 64.72 USD By Investing.com - Investing.com Australia
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - The Manila Times
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Does Oruka Therapeutics' (ORKA) US$1 Billion Shelf Clarify or Complicate Its Capital Strategy? - simplywall.st
ORKA Maintained by BTIG -- Price Target Raised to $78 - GuruFocus
H.C. Wainwright raises Oruka Therapeutics price target to $70 - Investing.com
H.C. Wainwright raises Oruka Therapeutics price target to $70 By Investing.com - Investing.com Canada
BTIG raises Oruka Therapeutics price target on trial timeline By Investing.com - Investing.com Canada
[EFFECT] Oruka Therapeutics, Inc. SEC Filing - Stock Titan
This Startup’s Psoriasis Drug Studies Have Lifted Its Stock - Barron's
Stifel reiterates Oruka Therapeutics stock rating ahead of trial data By Investing.com - Investing.com Canada
ORKA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Up Nearly 840% in a Year, Does This ‘Strong Buy’ Stock Have More Room to Run? - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5% After Analyst Upgrade - Defense World
How cyclical is Oruka Therapeutics Incs revenue streamPrice Action & Community Verified Watchlist Alerts - baoquankhu1.vn
Oruka Therapeutics Is Maintained at Overweight by Barclays - Moomoo
UBS Sticks to Its Buy Rating for Oruka Therapeutics (ORKA) - The Globe and Mail
Barclays Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $78 - Moomoo
Oruka Therapeutics (NASDAQ:ORKA) Given New $75.00 Price Target at UBS Group - Defense World
Does Oruka Therapeutics' (ORKA) $1 Billion Shelf Plan Reframe Its Long-Term Capital Strategy? - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $75.00 at UBS Group - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Hits New 52-Week HighHere's Why - MarketBeat
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $75 - Moomoo
Guggenheim raises Oruka Therapeutics price target on trial outlook By Investing.com - Investing.com Canada
Secure Asset Management LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
ORKA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oruka Therapeutics may offer up to $1 billion of securities from time to timeSEC filing - marketscreener.com
Oruka Therapeutics May Offer Up To $1 Billion Of Securities From Time To TimeSEC Filing - TradingView
Oruka Therapeutics (NASDAQ: ORKA) files $1B shelf to sell equity, warrants - Stock Titan
Oruka Therapeutics Stock Surges On Bullish Breakthrough - TipRanks
Oruka Therapeutics stock hits 52-week high at 50.11 USD By Investing.com - Investing.com Australia
HC Wainwright & Co. Maintains Oruka Therapeutics (ORKA) Buy Recommendation - MSN
ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors - TipRanks
Oruka Therapeutics stock hits 52-week high at 50.11 USD - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 18.4% in March - MarketBeat
How does Oruka Therapeutics Inc compare to its peersProfit Target & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Oruka Therapeutics and Clearmind Medicine Vie for Investor Dollars - National Today
Vanguard realignment leaves Oruka Therapeutics (ORKA) holdings at 0 after disaggregation - Stock Titan
458,946 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Synergy Asset Management LLC - marketbeat.com
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5.6%Here's Why - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD By Investing.com - Investing.com Australia
Momentum Shift: Will Oruka Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD - Investing.com
Aug Selloffs: Will Oruka Therapeutics Inc outperform tech stocksQuarterly Investment Review & AI Powered Market Entry Strategies - baoquankhu1.vn
Does Oruka’s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)? - Yahoo Finance
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight - Investing.com
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US6876041087 - marketscreener.com
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | HQ1 | US6876041087 - marketscreener.com
2.69%
0.25%
자본화:
|
볼륨(24시간):